Completed PHASE4 INTERVENTIONAL 1-arm NCT06032858

Efficacy and Safety of Apremilast in Psoriasis

Efficacy and Safety of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis

Sponsor: Ghurki Trust and Teaching Hospital

Conditions Psoriasis

Updated 3 times since 2023 Last updated: Sep 5, 2023 Started: Mar 6, 2022 Primary completion: Jul 10, 2023 Completion: Aug 10, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06032858, this PHASE4 trial focuses on Psoriasis and remains completed. Sponsored by Ghurki Trust and Teaching Hospital, it has been updated 3 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Oct 2023 — Jul 2024 [monthly]

Completed PHASE4

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ghurki Trust and Teaching Hospital

Data source: Ghurki Trust and Teaching Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lahore, Pakistan